Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 22;3(1):zcab009. doi: 10.1093/narcan/zcab009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of NAR Cancer.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — BMI1 regulates cholesterol metabolism in GBM. (A) Enrichment scores heatmap showing significant dysregulated molecular pathways (IPA software, - log10 of P-value < 0.05, P-score = or <1.3) upon BMI1, CBX8, RYBP or PRP6 silencing. (B) Log2 Fold change (Log2FC) of normalized gene counts heatmap showing differentially expressed genes (DEG) belonging to cholesterol metabolism (production and transport) in the shBMI1 dataset (IPA software, -log10 of P-value < 0.05, P-score = or <1.3). (C) Cell viability assay, assessed as relative luminescence units (RLU), in LN428^iCRempty versus LN428^iCRBMI1 in the presence of 5 μM DMSO, 80 ng/ml Simvastatin (Sim) or 5 μM PTC 209 (PTC) and in the combination of 80 ng/ml Simvastatin (Sim) and 5 μM PTC 209 (PTC) (n = 3; two-way ANOVA, ns, not significant, *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001). (D) Cell viability assay, assessed as relative luminescence units (RLU) in LN428^iCRempty versus LN428^iCRBMI1 in the presence of 5 μM DMSO, 2.5 mM U1866A (U18) or 5 μM PTC 209 (PTC) and in the combination of 2.5 mM U1866A (U18) and 5 μM PTC 209 (PTC) (n = 3, two-way ANOVA, ns, not significant, *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001). (E) Cell viability assay, as assessed by relative luminescence units (RLU) in LN428^aCRempty versus LN428^aCRBMI1 in the presence of 5 μM DMSO, 80 ng/ml Simvastatin (Sim) or 5 μM PTC 209 (PTC) and the combination of 80 ng/ml Simvastatin (Sim) and 5 μM PTC 209 (PTC) (n = 3, two-way ANOVA, ns, not significant, *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001). (F) Cell viability assay (relative luminescence units, RLU) in LN428^aCRempty versus LN428^aCRBMI1 in the presence of 5 μM DMSO, 2.5 mM U1866A (U18) or 5 μM PTC 209 (PTC) and the combination of 2.5 mM U1866A (U18) and 5 μM PTC 209 (PTC) respectively (n = 3, two-way ANOVA, ns, not significant, *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001).